𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levels of circulating immune complexes in patients with ovarian cancer

✍ Scribed by ANN G. CLARKE; D. P. VASEY; E. M. SYMONDS; B. FARATIAN; P. J. McLAUGHLIN; M. R. PRICE; R. W. BALDWIN

Book ID
111152516
Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
550 KB
Volume
89
Category
Article
ISSN
1470-0328

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical significance of circulating imm
Clinical significance of circulating immune complexes in patients with metastatic breast cancer
✍ G. Krieger; A. Kehl; H.-E. Wander; A.-M. Salo; H. F. Rauschecker; G. A. Nagel πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 French βš– 541 KB

## Abstract Serum circulating immune complexes (CIC) were repeatedly measured by means of the Cl binding assay (Cba) and the Raji cell assay (Rca) in 158 patients with metastatic breast cancer (mbc). Frequency of occurrence and levels of CIC were only slightly increased in mbc when compared to age‐

A prospective study of circulating immun
A prospective study of circulating immune complexes in patients with breast cancer
✍ A. Bukh; M. T. Aguado; N. Krarup; H. S. Poulsen; A. M. Nordentoft; N. P. H. Moll πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 French βš– 795 KB

Levels of circulating immune complex (clC) and complement split product C3d were studied in 86 patients with breast cancer (BC), 22 patients with benign breast disease (BD), and 72 age-and sex-matched blood-bank donors (NC), using solidphase Clq-protein A RIA, C I q-anti-lgG RIA, anti-C3d anti-lgG R

Circulating immune complexes in patients
Circulating immune complexes in patients with bone tumours
✍ Amada Segal Eiras; R. A. Robins; R. W. Baldwin; V. S. Byers πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 French βš– 456 KB

## Abstract Sera from 62 patients with osteogenic sarcoma and 12 with malignant giant‐cell tumour were tested for the presence of immune complexes by the ^125^I‐Clq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giant‐cell